Genitourinary Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers Global Genitourinary Drugs Market Forecast & Share and it is Segmented by Disease Type (Erectile Dysfunction, Gonorrhea, Genital Herpes, Urinary Tract Infections, Urinary Incontinence, Glomerulonephritis, Chronic renal failure, Other Disease Types), Drug Type (Hormonal Therapy, Impotence Agents, Uterine Relaxants, Urinary Antispasmodics, Urinary pH Modifiers, Uterine Stimulants, Miscellaneous Genitourinary Tract Agents), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market provides the value (in USD million) for the above segments.

Genitourinary Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Genitourinary Drugs Market Size

Genitourinary Drugs Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
CAGR 2.90 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Low

Major Players

Genitourinary Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Genitourinary Drugs Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Genitourinary Drugs Market Analysis

The Global Genitourinary Drugs Market is expected to register a CAGR of 2.9% during the forecast period.

Initially, COVID-19 impacted the studied market owing to cancellations of elective procedures, including genitourinary tract infection treatments. Also, COVID-19 infection had been reported to worsen the symptoms of people with genitourinary disorders. For instance, according to an article published in the Asian Journal of Urology in July 2021, coronaviruses could cause urological symptoms when they infect the genitourinary system. COVID-19 was responsible for genitourinary organ dysfunction and damage. Patients with COVID-19 were found to have kidney impairment in several studies. Some research studies indicated that COVID-19 infection poses the greatest threat to the respiratory, digestive, and reproductive systems. Therefore, the genitourinary market was significantly impacted by COVID-19 in its initial phase. However, post-pandemic, the market started to recover since the restrictions were lifted and elective procedures resumed worldwide. The market is expected to gain pace during the forecast period owing to rising research and development activities for innovation in genitourinary drugs.

The high burden of genitourinary disorders is expected to create opportunities for market players' product innovation and launches which is expected to propel market growth. For instance, as per the report published by the World Health Organization in November 2021, more than 1.0 million sexually transmitted infections are acquired globally and most of them are asymptomatic. Sexually transmitted infections (STIs) are associated with genitourinary complications which are projected to propel the demand for developing a genitourinary drug for the effective treatment of such diseases, thereby fueling the growth of the market.

Furthermore, the high prevalence of urinary tract infections and urinary incontinence is also contributing to the market growth. For instance, according to a Statpearls article updated in August 2022, it is estimated that around 423 million people (20 years and older) worldwide experience some form of urinary incontinence. The high burden of urinary incontinence globally is expected to propel the market growth.

Additionally, increasing investments in research and developments (R&D) activities for developing novel molecules for treating genitourinary diseases, and an increasing number of pipeline drugs are expected to drive the market during the forecast period. For instance, in February 2022, Asieris Pharmaceuticals received the clinical trial application (CTA) approval for Hexvix, a drug for the diagnosis of bladder cancer, from the National Medical Products Administration (NMPA) of China.

However, increasing counterfeit drugs and a lack of awareness about infections and treatment medications are expected to restrain the genitourinary drug market.

Genitourinary Drugs Industry Overview

The genitourinary drugs market is moderately competitive in nature. Major market players are investing high capital in R&D and adopting many strategies, such as new product launches and developments, geographical expansions, collaborations, and acquisitions, to strengthen their market position in the global genitourinary drugs market. Some key market players include Merck and Co. Inc., Cipla Inc., Pfizer, Allergen, and Melinta Therapeutics Inc, among others.

Genitourinary Drugs Market Leaders

  1. Melinta Therapeutics Inc.

  2. Merck & Co. Inc.

  3. Pfizer Inc.

  4. GlaxoSmithKline

  5. Cipla Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Genitourinary Drugs Market.png
Need More Details on Market Players and Competiters?
Download PDF

Genitourinary Drugs Market News

  • In November 2022, GSK PLC reported that a new drug, called gepotidacin, was effective in two large clinical trials involving approximately 3,000 patients for treating urinary tract infections.
  • In February 2022, Veru presented the updated data from the phase 1b/2 Sabizabulin study in men with metastatic castration-resistant prostate cancer at the 2022 ASCO genitourinary cancers symposium.

Genitourinary Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Genitourinary Disorders
    • 4.2.2 Increasing Number of Pipeline Products
  • 4.3 Market Restraints
    • 4.3.1 Lack of Therapy Compliance
    • 4.3.2 Increasing Advent of Counterfeit Drugs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Disease Type
    • 5.1.1 Erectile dysfunction
    • 5.1.2 Gonorrhoea
    • 5.1.3 Genital Herpes
    • 5.1.4 Urinary Tract Infections
    • 5.1.5 Urinary Incontinence
    • 5.1.6 Glomerulonephritis
    • 5.1.7 Chronic renal failure
    • 5.1.8 Other Disease Types
  • 5.2 By Drug Type
    • 5.2.1 Hormonal Therapy
    • 5.2.2 Impotence Agents
    • 5.2.3 Uterine Relaxants
    • 5.2.4 Urinary Antispasmodics
    • 5.2.5 Urinary pH Modifiers
    • 5.2.6 Uterine Stimulants
    • 5.2.7 Miscellaneous Genitourinary Tract Agents
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Eli Lilly and Company
    • 6.1.2 GlaxoSmithKline PLC
    • 6.1.3 Cipla Inc.
    • 6.1.4 Melinta Therapeutics Inc.
    • 6.1.5 Merck & Co. Inc.
    • 6.1.6 Novartis AG
    • 6.1.7 Pfizer Inc.
    • 6.1.8 Bayer AG
    • 6.1.9 F. Hoffmann-La Roche Ltd
    • 6.1.10 Camber Pharmaceuticals, Inc.
    • 6.1.11 Viatris Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Genitourinary Drugs Industry Segmentation

As per the scope of the report, genitourinary drugs are used to treat disorders affecting the kidneys, bladder, ureters, and urethra. Patients suffering from diseases and infections related to genitourinary systems have been depending on steroids and immunosuppressants, which are chemically synthesized and may reciprocate with severe side effects such as insomnia, acne, nausea, vomiting, and diarrhea. 

The Genitourinary Drugs Market is Segmented by Disease Type (Erectile dysfunction, Gonorrhoea, Genital Herpes, Urinary Tract Infections, Urinary Incontinence, Glomerulonephritis, Chronic renal failure, Other Disease Types), Drug Type (Hormonal Therapy, Impotence Agents, Uterine Relaxants, Urinary Antispasmodics, Urinary pH Modifiers, Uterine Stimulants, Miscellaneous Genitourinary Tract Agents), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.

By Disease Type Erectile dysfunction
Gonorrhoea
Genital Herpes
Urinary Tract Infections
Urinary Incontinence
Glomerulonephritis
Chronic renal failure
Other Disease Types
By Drug Type Hormonal Therapy
Impotence Agents
Uterine Relaxants
Urinary Antispasmodics
Urinary pH Modifiers
Uterine Stimulants
Miscellaneous Genitourinary Tract Agents
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Genitourinary Drugs Market Research FAQs

What is the current Global Genitourinary Drugs Market size?

The Global Genitourinary Drugs Market is projected to register a CAGR of 2.9% during the forecast period (2025-2030)

Who are the key players in Global Genitourinary Drugs Market?

Melinta Therapeutics Inc., Merck & Co. Inc., Pfizer Inc., GlaxoSmithKline and Cipla Inc. are the major companies operating in the Global Genitourinary Drugs Market.

Which is the fastest growing region in Global Genitourinary Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Genitourinary Drugs Market?

In 2025, the North America accounts for the largest market share in Global Genitourinary Drugs Market.

What years does this Global Genitourinary Drugs Market cover?

The report covers the Global Genitourinary Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Genitourinary Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Genitourinary Drugs Industry Report

Statistics for the 2025 Global Genitourinary Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Genitourinary Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Genitourinary Drugs Market Report Snapshots